{"entity":{"id":"ctx112","kind":"drug","name":"CTX112","aka":[],"tldr":"CTX112 is an experimental CAR-T cell therapy from CRISPR Therapeutics in phase 2 trials for hodgkin lymphoma, chronic lymphocytic leukaemia and follicular lymphoma, aimed at CD19.","summary":"CTX112 is a CAR-T cell therapy developed by CRISPR Therapeutics. Its target is CD19 (the sponsor names CD19). The sponsor states: An allogeneic CD19-directed CAR T-cell immunotherapy made from donor T cells genetically modified ex vivo using CRISPR-Cas9 gene editing (single guide RNA and Cas9 nuclease) to attack CD19-expressing B-cell malignancies. ClinicalTrials.gov describes the intervention as: CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma, chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma. The largest, NCT05643742, plans to enrol 120 participants with primary completion expected 2030-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of CTX112","url":"https://clinicaltrials.gov/search?intr=CTX112"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma","cll","follicular-lymphoma","mantle-cell-lymphoma","dlbcl"],"sections":[],"technologies":[],"targets":["cd19"],"drugs":[],"companies":["crispr-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05643742"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"CAR-T cell therapy","mechanism":"An allogeneic CD19-directed CAR T-cell immunotherapy made from donor T cells genetically modified ex vivo using CRISPR-Cas9 gene editing (single guide RNA and Cas9 nuclease) to attack CD19-expressing B-cell malignancies.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ctx112/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"crispr-therapeutics","kind":"company","name":"CRISPR Therapeutics","route":"/companies/crispr-therapeutics/"}],"trial":[{"id":"nct05643742","kind":"trial","name":"A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies","route":"/trials/nct05643742/"}]}}